FDC inches up on getting final nod for Cefixime 400 mg Tablets
FDC is currently trading at Rs. 515.05, up by 0.50 points or 0.10% from its previous closing of Rs. 514.55 on the BSE.
The scrip opened at Rs. 513.95 and has touched a high and low of Rs. 518.70 and Rs. 506.30 respectively. So far 2256 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 659.00 on 12-Sep-2024 and a 52 week low of Rs. 375.65 on 21-Dec-2023.
Last one week high and low of the scrip stood at Rs. 519.65 and Rs. 494.60 respectively. The current market cap of the company is Rs. 8385.53 crore.
The promoters holding in the company stood at 69.66% while Institutions and Non-Institutions held 8.65% and 21.70% respectively.
FDC has received final approval from U.S. Food and Drug Administration (USFDA) for the Company’s Abbreviated New Drug Application (ANDA) for Cefixime 400 mg Tablets.
In November 2024, FDC recalled 1,55,232 bottles of Timolol Maleate ophthalmic solution in the US market. The company recalled the affected lot due to ‘Defective Container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle.’
FDC is among India’s leading fully integrated pharmaceutical companies.
